EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Targeted Therapy for Highly Desmoplastic and Immunosuppressive Tumor Microenvironment of Pancreatic Ductal Adenocarcinoma

Olamide T Olaoba iD, Ming Yang, Temitope I Adelusi, Tessa Maidens iD, Eric T Kimchi iD, Kevin F Staveley-O'Carroll, Guangfu Li

Cancers · 11.04.2024 · 16 (8) · 1470

DOI: 10.3390/cancers16081470 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 11.04.2024. Verfasst von Olamide T Olaoba und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, University of Missouri, Columbia, MO 65212, USA. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 136 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Missouri, Gift Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal malignancy with a very poor prognosis. Despite advancements in treatment strategies, PDAC remains recalcitrant to therapies because patients are often diagnosed at an advanced stage. The advanced stage of PDAC is characterized by metastasis, which typically renders it unresectable by surgery or untreatable by chemotherapy. The tumor microenvironment (TME) of PDAC comprises highly proliferative myofibroblast-like cells and hosts the intense deposition of a extracellular matrix component that forms dense fibrous connective tissue, a process called the desmoplastic reaction. In desmoplastic TMEs, the incessant aberration of signaling pathways contributes to immunosuppression by suppressing antitumor immunity. This feature offers a protective barrier that impedes the targeted delivery of drugs. In addition, the efficacy of immunotherapy is compromised because of the immune cold TME of PDAC. Targeted therapy approaches towards stromal and immunosuppressive TMEs are challenging. In this review, we discuss cellular and non-cellular TME components that contain actionable targets for drug development. We also highlight findings from preclinical studies and provide updates about the efficacies of new investigational drugs in clinical trials.

Schlagwörter

Stichwörter der Autor:innen

PDACdesmoplasiaimmunotherapytargeted therapytumor microenvironment

Autor:innen und Institutionen

  • Department of Surgery, University of Missouri, Columbia, MO 65212, USA.
  • Department of Molecular Microbiology and Immunology, University of Missouri, Columbia, MO 65212, USA.
  • Roy Blunt NextGen Precision Health Institute, University of Missouri, Columbia, MO 65212, USA.
  • Harry S. Truman Memorial Veterans' Hospital, Columbia, MO 65201, USA.
  • Ellis Fischel Cancer Center, University of Missouri, Columbia, MO 65212, USA.

ORCID-Profile: Olamide T Olaoba, Tessa Maidens, Eric T Kimchi

Förderung

  • University of Missouri
  • Gift Fund

Zitieren

APA

Olaoba, O. T., Yang, M., Adelusi, T. I., Maidens, T., Kimchi, E. T., Staveley-O'Carroll, K. F., & Li, G. (2024). Targeted Therapy for Highly Desmoplastic and Immunosuppressive Tumor Microenvironment of Pancreatic Ductal Adenocarcinoma. Cancers, 16(8), 1470. https://doi.org/10.3390/cancers16081470

Vancouver

Olaoba OT, Yang M, Adelusi TI, Maidens T, Kimchi ET, Staveley-O'Carroll KF, et al. Targeted Therapy for Highly Desmoplastic and Immunosuppressive Tumor Microenvironment of Pancreatic Ductal Adenocarcinoma. Cancers. 2024;16(8):1470. doi:10.3390/cancers16081470

BibTeX
@article{Olaoba2024,
  author = {Olaoba, Olamide T and Yang, Ming and Adelusi, Temitope I and Maidens, Tessa and Kimchi, Eric T and Staveley-O'Carroll, Kevin F and Li, Guangfu},
  title = {Targeted Therapy for Highly Desmoplastic and Immunosuppressive Tumor Microenvironment of Pancreatic Ductal Adenocarcinoma},
  journal = {Cancers},
  year = {2024},
  volume = {16},
  number = {8},
  pages = {1470},
  doi = {10.3390/cancers16081470}
}
Kostenlos starten →